Latest news with #Tenecteplase
Time of India
3 days ago
- Health
- Time of India
‘STEMI to ensure no heart patient in UP dies due to lack of treatment'
1 2 3 4 5 6 Lucknow: Heart patients in UP will soon be able to receive timely treatment at their nearest district hospital or community health centre, with the 'System of Treating Elevation Myocardial Infarction' (STEMI) care network. The initiative aims to provide advanced cardiac care during the critical 'golden hour' following a heart attack, increasing the chances of survival for patients even in remote areas. To support this, a three-day Training of Trainers (ToT) workshop began at Ram Manohar Lohia Institute of Medical Sciences (RMLIMS). The workshop is focused on training healthcare professionals, including doctors, staff nurses, and paramedics, to implement standardised STEMI protocols in their respective districts. These protocols are designed to ensure early diagnosis, prompt administration of medication, and timely patient transfer to higher centres when needed. Inaugurating the workshop, principal secretary of medical health & family welfare and medical education, Partha Sarthi Sen Sharma, emphasised the govt's vision of expanding emergency cardiac services across the state. He assured that there would be no shortage of Tenecteplase, the clot-dissolving drug used in heart attack cases, and that it would be made available even at the most remote healthcare centres. "Our goal is to ensure that no patient in Uttar Pradesh loses their life due to the non-availability of timely heart attack treatment," he said. The STEMI care network is based on a hub-and-spoke model. RMLIMS, through its cardiology department, will function as the central hub providing specialist oversight, ECG interpretation, and advanced intervention facilities. District hospitals in Ayodhya, Devipatan range, Sultanpur, and other regions will serve as spoke hospitals. These centres will be responsible for early diagnosis and initiation of treatment under the guidance of the hub. Dr Bhuwan Tiwari, head of cardiology at RMLIMS, explained the structure of the STEMI CARE protocol during the workshop. He introduced a step-by-step acronym that guides healthcare providers in managing heart attack patients. "The power of this program lies in empowering frontline health workers to act swiftly and correctly," he said. The acronym STEMI CARE stands for: Symptoms (identify cardiac symptoms), Time (note when symptoms started), ECG (perform and interpret a 12-lead ECG), Medical Management (give aspirin, clopidogrel, and atorvastatin), Initiate Thrombolysis (administer Tenecteplase if needed), Call the Hub (share patient data with the tertiary centre), Ambulance (arrange transfer with oxygen and IV access), Reassess (monitor vitals before transfer), and Ensure Handover (send referral documents with the patient). Senior cardiologist Dr Rishi Sethi from KGMU spoke about the clinical importance of timely STEMI care'. Varanasi CMO Dr Sandeep Chaudhary shared practical experiences from the field.
Mid East Info
28-02-2025
- Health
- Mid East Info
Boehringer Ingelheim Launches Fast-acting Stroke Medication in the UAE, Reducing Treatment Administration to Five Seconds
The newly approved treatment provides a fast-acting option for acute ischemic stroke (AIS) care. Administered as a single IV bolus over a period of five to ten seconds, the treatment offers a significant improvement over regular one-hour-long treatments. Dubai, United Arab Emirates – February 2025: Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has launched a new acute ischemic stroke (AIS) medication with active ingredient Tenecteplase 25mg to enhance emergency stroke treatment in the UAE, offering a faster and more effective treatment option for emergency stroke care. Launched in the UAE for the first time across the India, Middle East, Turkey and Africa region, the new medication can be delivered over five to ten seconds, compared to the previous treatments requiring a one-hour administration process. This simplified and rapid approach facilitates faster treatment administration in emergency settings, reducing both door-to-needle (DTN) times and door-in-door-out (DIDO) times. This can improve patient recovery outcomes and minimize long-term neurological deficits associated with stroke [i] . Stroke is the second leading cause of death globally and a major contributor to disability, thereby imposing significant burdens on both patients and the economy [ii] . Many survivors face long-term disabilities, with up to 50% being chronically disabled [iii] . In the UAE, between 8,000 to 10,000 individuals suffer from a stroke each year, which amounts to one case every hour [iv] . Ischemic strokes occur when there is a blockage in a blood vessel, resulting in reduced blood supply to the brain [v] . Early recognition of symptoms is crucial for effective treatment. Common signs include sudden numbness or weakness, especially on one side of the body; confusion or trouble speaking; difficulty seeing in one or both eyes; dizziness or loss of balance; and a severe headache with no known cause [vi] . The new medication was launched on 22 February during the 5th Dubai Neurology Congress, which brought together over 120 healthcare professionals from the UAE. Dr. Suhail Al Rukn, President of the Emirates Neurology Society and Consultant Neurologist highlighted the importance of time efficiency in stroke care. 'Time is brain,' Dr. Al Rukn said. 'Reducing the time between symptoms onset and treatment is crucial in saving lives and preserving brain function [vii] . For every minute that treatment is delayed, millions of brain cells are lost [viii] . Seeking immediate medical care can therefore greatly improve outcomes and minimize the risk of long-term disability. This new treatment offers a major leap forward by minimizing delays and simplifying the administration process, providing an opportunity to improve outcomes for stroke patients in the UAE.' Ousama Alhaj, General Manager and Head of Human Pharma, Boehringer Ingelheim in the Near East and UAE added: 'The UAE, like many other countries around the world, faces a growing incidence of stroke cases each year [ix] , making timely treatment a priority. This new medication not only improves the efficiency of care delivery but also enhances the overall healthcare journey for patients. At Boehringer Ingelheim, we are committed to developing patient-centered health solutions that improve survival rates and long-term outcomes for stroke patients. We also remain committed to working closely with healthcare stakeholders to ensure these medications are accessible to those who need them.' Administered at a dose of 0.25mg/kg (up to a maximum of 25mg) as a single intravenous bolus, the new treatment is now available in the UAE and underscores Boehringer Ingelheim's ongoing dedication to patient-centered innovation in healthcare, with a focus on early detection, prevention, and treatment. The company continues to strengthen its presence in the UAE by providing advanced medical solutions that address the needs of healthcare professionals and patients alike. About Boehringer Ingelheim: Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
Web Release
27-02-2025
- Health
- Web Release
Boehringer Ingelheim Launches Fast-acting Stroke Medication in the UAE, Reducing Treatment Administration to Five Seconds
Health Web Release Selection By Editor_wr On Feb 27, 2025 Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has launched a new acute ischemic stroke (AIS) medication with active ingredient Tenecteplase 25mg to enhance emergency stroke treatment in the UAE, offering a faster and more effective treatment option for emergency stroke care. Launched in the UAE for the first time across the India, Middle East, Turkey and Africa region, the new medication can be delivered over five to ten seconds, compared to the previous treatments requiring a one-hour administration process. This simplified and rapid approach facilitates faster treatment administration in emergency settings, reducing both door-to-needle (DTN) times and door-in-door-out (DIDO) times. This can improve patient recovery outcomes and minimize long-term neurological deficits associated with stroke . Stroke is the second leading cause of death globally and a major contributor to disability, thereby imposing significant burdens on both patients and the economy . Many survivors face long-term disabilities, with up to 50% being chronically disabled . In the UAE, between 8,000 to 10,000 individuals suffer from a stroke each year, which amounts to one case every hour . Ischemic strokes occur when there is a blockage in a blood vessel, resulting in reduced blood supply to the brain . Early recognition of symptoms is crucial for effective treatment. Common signs include sudden numbness or weakness, especially on one side of the body; confusion or trouble speaking; difficulty seeing in one or both eyes; dizziness or loss of balance; and a severe headache with no known cause . The new medication was launched on 22 February during the 5th Dubai Neurology Congress, which brought together over 120 healthcare professionals from the UAE. Dr. Suhail Al Rukn, President of the Emirates Neurology Society and Consultant Neurologist highlighted the importance of time efficiency in stroke care. 'Time is brain,' Dr. Al Rukn said. 'Reducing the time between symptoms onset and treatment is crucial in saving lives and preserving brain function . For every minute that treatment is delayed, millions of brain cells are lost . Seeking immediate medical care can therefore greatly improve outcomes and minimize the risk of long-term disability. This new treatment offers a major leap forward by minimizing delays and simplifying the administration process, providing an opportunity to improve outcomes for stroke patients in the UAE.' Ousama Alhaj, General Manager and Head of Human Pharma, Boehringer Ingelheim in the Near East and UAE added: 'The UAE, like many other countries around the world, faces a growing incidence of stroke cases each year , making timely treatment a priority. This new medication not only improves the efficiency of care delivery but also enhances the overall healthcare journey for patients. At Boehringer Ingelheim, we are committed to developing patient-centered health solutions that improve survival rates and long-term outcomes for stroke patients. We also remain committed to working closely with healthcare stakeholders to ensure these medications are accessible to those who need them.' Administered at a dose of 0.25mg/kg (up to a maximum of 25mg) as a single intravenous bolus, the new treatment is now available in the UAE and underscores Boehringer Ingelheim's ongoing dedication to patient-centered innovation in healthcare, with a focus on early detection, prevention, and treatment. The company continues to strengthen its presence in the UAE by providing advanced medical solutions that address the needs of healthcare professionals and patients alike.
CBS News
28-01-2025
- Health
- CBS News
Quick-thinking American Legion post employees save veteran's life by recognizing stroke symptoms
BALTIMORE -- Quick action by two American Legion Post employees helped save the life of a 79-year-old Vietnam veteran suffering a stroke, demonstrating the critical importance of recognizing stroke symptoms early. LeRoy Peyton, who volunteers with the Armed Forces Visitation Program at Upper Chesapeake Health, was at the American Legion Post when bartender Donna King and assistant manager LeeAnne Axelsson noticed his face discoloring and speech becoming unclear. "He was unable to communicate, he had a voice, but it was not making sense and I knew right away we needed to get him out of here. Because time is so critical and if it was a stroke and I was sure it was a stroke," King said. Paramedics rushed Peyton to the hospital, where he received a clot-busting drug that Lindsay Goff, Stroke Program Coordinator at Upper Chesapeake, credits for his recovery. "He did have significant levels of neurologic deficit... I'm thankful that Tenecteplase got him back to his baseline," Goff said. Today, aside from mild facial numbness, Peyton has made a full recovery and continues his volunteer work visiting veteran patients. Medical experts use the acronym BEFAST to identify stroke symptoms: Balance issues, Eye problems, Face drooping, Arm weakness, Speech difficulty, and Time to call 911. Stroke is the fifth leading cause of death in the U.S. and a leading cause of disability, though up to 80% of strokes can be prevented.
